SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 02:00:17 2024-07-11 pm EDT | ||
| 3.96 EUR | -0.75% |
|
| Current month | -0.75% | ||
| 1 month | +1.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 3.96 | -0.75% |
| 24-07-10 | 3.99 | -0.99% |
| 24-07-09 | 4.03 | -0.98% |
| 24-07-08 | 4.07 | -1.21% |
| 24-07-05 | 4.12 | +1.73% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 02:00 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VX9JAN |
| ISIN | DE000VX9JAN0 |
| Date issued | 2022-04-04 |
| Strike | 84.12 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.14 € |
|---|---|
| Lowest since issue | 0.49 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.75
USD
Average target price
52.92
USD
Spread / Average Target
+29.87%
- Stock Market
- Certificates
- Certificat
